Skip to main content

Table 2 Overview of treatment, artemisinin combination treatment dosing and formulation

From: Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data

 

Treatment

Dosing

 

n evaluated

N (%)

n evaluated

Partner drug dose median (Range)

Artemisinin derivative dose median (Range)

Underdosed n (%)

AL

48840

13217 (27 %)

13086

68.6 (8.9–144.0)

11.4 (1.5–24.0)

1008 (8.3 %)

AS-AQ

48840

8488 (17 %)

8395

31.9 (10.0–91.8)

12.4 (4.0–52.6)

 

AS-AQ formulation:

      

 Co-blistered nFDC

8488

573 (7 %)

573

37.4 (14.8–91.8)

13.5 (4.8–30.0)

 

 FDC

8488

4278 (50 %)

4262

32.4 (14.5–81.0)

12.0 (5.4–30.0)

2 (0.1 %)

 nFDC

8488

3637 (43 %)

3560

30.1 (10.0–60.0)

12.5 (4.0–52.6)

 

AS-MQ

48840

5198 (11 %)

4535

25.0 (4.2–85.0)

12.0 (2.3–62.1)

38 (0.8 %)

DP

48840

6453 (13 %)

6315

53.3 (14.5–182.9)

6.7 (1.8–22.9)

1488 (23.6 %)

Other, including non-ACT

48840

15484 (32 %)

    
  1. AL, Artemether-Lumefantrine; AS-AQ, Artesunate-Amodiaquine; AS-MQ, Artesunate-Mefloquine; DP, Dihydroartemisinin-piperaquine; nFDC, Non-fixed dose combination, FDC, Fixed dose combination; Underdosed defined as ≤ 8.4 mg/kg artemether dose in AL, < 6 mg/kg dose of artesunate or DHA in other regimens [19]